Managing Hypotension Risk During GLP-1 Treatment If you have low blood pressure and your provider approves semaglutide therapy, several practical steps reduce hypotension risk
Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. International Journal of Obesity
Glucagon has been shown to activate brown adipose tissue in animal models, increasing thermogenesis and energy expenditure
Liraglutide (Victoza/Saxenda) Approved in 2010, Saxenda (liraglutide) was the first GLP-1 medication approved for weight loss in adults with obesity or overweight with at least one weight-related health issue
PubMed Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D.S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., & Kolenc, D